NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
RefinitivMoins d'1 minute de lecture
Neuropace Inc 
NPCE:
NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE
NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY
NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT
NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM
NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION
Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles